Dimensional Fund Advisors LP Invests $940,000 in Unicycive Therapeutics, Inc. $UNCY

Dimensional Fund Advisors LP acquired a new stake in shares of Unicycive Therapeutics, Inc. (NASDAQ:UNCY) during the first quarter, HoldingsChannel.com reports. The firm acquired 143,052 shares of the company’s stock, valued at approximately $940,000.

Several other institutional investors have also recently made changes to their positions in UNCY. Lazard Asset Management LLC purchased a new position in shares of Unicycive Therapeutics during the second quarter valued at approximately $55,000. JPMorgan Chase & Co. raised its holdings in shares of Unicycive Therapeutics by 11,698.4% in the second quarter. JPMorgan Chase & Co. now owns 21,709 shares of the company’s stock valued at $104,000 after acquiring an additional 21,525 shares in the last quarter. Citadel Advisors LLC purchased a new stake in shares of Unicycive Therapeutics in the 3rd quarter worth approximately $182,000. Quadrature Capital Ltd bought a new stake in Unicycive Therapeutics during the 4th quarter valued at $226,000. Finally, State Street Corp grew its stake in Unicycive Therapeutics by 19.0% in the fourth quarter. State Street Corp now owns 65,227 shares of the company’s stock valued at $376,000 after purchasing an additional 10,400 shares during the last quarter. Institutional investors own 40.42% of the company’s stock.

Unicycive Therapeutics Price Performance

NASDAQ:UNCY opened at $5.51 on Friday. The company has a 50 day moving average price of $5.94 and a 200-day moving average price of $6.64. The firm has a market cap of $153.45 million, a price-to-earnings ratio of -3.15 and a beta of 1.79. Unicycive Therapeutics, Inc. has a 1-year low of $3.71 and a 1-year high of $8.74.

Unicycive Therapeutics (NASDAQ:UNCY) last posted its earnings results on Wednesday, August 12th. The company reported ($0.06) EPS for the quarter, beating analysts’ consensus estimates of ($0.47) by $0.41. On average, sell-side analysts anticipate that Unicycive Therapeutics, Inc. will post -1.43 earnings per share for the current fiscal year.

Analyst Ratings Changes

UNCY has been the subject of a number of research analyst reports. Guggenheim reiterated a “buy” rating and issued a $25.00 price target (down from $37.00) on shares of Unicycive Therapeutics in a research note on Thursday. Weiss Ratings upgraded Unicycive Therapeutics from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Tuesday, June 9th. Wall Street Zen raised Unicycive Therapeutics from a “sell” rating to a “hold” rating in a report on Saturday. Zacks Research cut Unicycive Therapeutics from a “hold” rating to a “strong sell” rating in a research note on Tuesday, July 21st. Finally, Benchmark decreased their target price on Unicycive Therapeutics from $18.00 to $13.00 and set a “speculative buy” rating for the company in a report on Wednesday, July 1st. Five analysts have rated the stock with a Buy rating and two have given a Sell rating to the stock. Based on data from MarketBeat, the stock has an average rating of “Hold” and a consensus target price of $18.25.

Unicycive Therapeutics Profile

Unicycive Therapeutics, Inc, a biotechnology company, engages in developing novel therapies for kidney diseases in the United States. It is developing Renazorb for treatment of hyperphosphatemia in patients with chronic kidney disease on dialysis; and UNI 494, which is in Phase 1 clinical trials for treatment of acute kidney injury. The company was incorporated in 2016 and is based in Los Altos, California.